2,841 research outputs found
Utilizzo terapeutico di un dominio della proteina umana LGALS3BP denominato D2 nell’arteriopatia obliterante periferica e nelle ulcere cutanee croniche. Therapeutic use of a domain of the human LGALS3BP protein called D2 in peripheral arterial disease and chronic skin ulcers.
No full textLa presente invenzione riguarda l’utilizzo farmacologico di uno specifico dominio della proteina umana LGALS3BP (nota anche come Mac-2 BP o Gal-3BP o 90K) caratterizzato dalla sequenza amminoacidica riportata nella tabella 1 e qui denominato D2. Gli inventori hanno scoperto che tale dominio è in grado di mediare processi fisiologici, incluso la rigenerazione tissutale e l’angiogenesi, che sono essenziali per la
cura delle patologie ischemiche e la guarigione delle ulcere diabetiche del piede. Per tali patologie non esistono attualmente farmaci efficaci e specifici, compresi gli antiinfiammatori.
Nella presente invenzione viene dimostrato che la somministrazione di
D2 a dosi inferiori a 1 mg, porta a una significativa riduzione del tempo di guarigione di ferite sperimentali nell’animale e a un aumento del flusso sanguigno in un modello murino di ischemia degli arti posteriori. La sostituzione di alcuni aminoacidi con altri amino acidi (< 5% del totale) nella sequenza di D2 non porta a sostanziali modifiche
dell’attività farmacologica
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR
No full textWho is the author of the 1876 Stefano manuscript?
No full textFor over one hundred years the Stefano manuscript was a private document in the possession of the Baccich family and descendants. It told a story of the 1875 Stefano shipwreck as narrated by the shipwreck survivor and the founding family patriarch Miho Baccich. In these circumstances the question of authorship of the manuscript was immaterial and did not arise as an issue. However, with the publication of the manuscript the author‟s name, or names, need to be formally attributed to it. It turns out that this is not such a clear-cut matter.
As we shall see, all informed sources attributed the authorship, and the ownership, of the manuscript to Miho Baccich. But the manuscript itself was written by Canon Stjepan Skurla – a priest from Miho‟s hometown of Dubrovnik. The question then arises: should Skurla also be considered as an author of the manuscript, or, even as the sole author (as some would have it)
Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines
No full textCOVID‐19 is the global pandemic that affected our population in the past 2 years. Considerable research has been done to better understand the pathophysiology of this disease and to identify new therapeutic targets, especially for severe cases. Galectin‐3 (Gal‐3) is a receptor present at the surface of different cell types, namely epithelial and inflammatory cells, which has been described as a severity marker in COVID‐19. The activation of Gal‐3 through its binding protein (Gal‐3BP) is directly linked to the production of pro‐inflammatory cytokines that contribute for the cytokine storm (CS) observed in severe COVID‐19 patients. Here, we show that D2, a recombinant fragment of the lectin‐binding region of Gal‐3BP was able to stimulate the expression of IL‐6 in colon and lung epithelial cell lines in β‐galactoside dependent manner. We further show that D2‐induced IL‐6 augmentation was reduced by the anti‐Gal‐3BP monoclonal antibody 1959. Our data confirm and extend prior findings of Gal‐3BP mediated IL‐6 induction, enlightening the potential of its antibody‐mediated s blockage for the prevention and treatment of CS and severe disease in COVID‐19 patients
Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer
No full textCirculating autoantibodies have been extensively investigated as possible markers for early diagnosis of cancer. The present study was carried out to investigate whether anti-LGALS3BP IgG autoantibodies could be classified as a biomarker for malignant tumors. Methods. An in-house developed enzyme-linked immunosorbent assay was used to detect autoantibodies to LGALS3BP in sera from 71 patients with various types of cancers and 54 healthy subjects matched by age and gender. Results. Patients with cancer have significant higher circulating levels of anti-LGALS3BP antibodies as compared to control subjects ( ). The test has a sensitivity of 33% and a specificity of 98%. Conclusions. Anti-LGALS3BP IgG autoantibodies are a promising biomarker for malignant tumors and could play a role in the development of a multimarker assay for the early detection of cancer
The glycoprotein 90K/Mac-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation
No full text
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer
No full textIncreased Gal‐3BP plasma levels in hospitalized patients infected with SARS‐CoV‐2
No full textCoronavirus disease 2019 (COVID-19) has quickly turned into a health, fnancial and societal problem globally. The complex pathogenesis of severe acute respiratory syndrome coronavirus centers on the unpredictable clinical progression of the
disease, which may evolve abruptly and results in critical and life-threatening clinical complications. Efective laboratory
biomarkers that can classify patients according to risk of progression to severe disease are essential for ensuring timely treatment. Gal-3BP is a human secreted protein with innate immune functions, which is upregulated in viral infections, promotes infammation and has been shown to induce IL-6 expression. In this study, Gal-3BP plasma levels were measured retrospectively in a cohort of 84 hospitalized COVID-19 patients. These were classifed as having either “non-severe” or “severe” disease. Compared to healthy controls, Gal-3BP plasma levels were markedly increased in COVID-19 patients (P< 0.0001). Moreover, the levels were higher in severe than in non-severe patients (P < 0.05). As expected, patients with severe disease had plasma levels of IL-6 higher than patients with non-severe disease (P < 0.01). In non-severe disease patients, Gal-3BP levels collected at a late stage (13.3 + 5.7 days after the frst positive PCR result) were signifcantly lower than those collected at an early stage (4.2 + 2.9 days form the frst positive PCR result). Larger prospective analyses are needed to strength our understanding of the prognostic utility of Gal-3BP in COVID-19 patients
- …
